Therefore, it is now clear that maintaining the epithelium in the prostate is an important molecular mechanism for inhibiting tumorigenesis, and ESRP1 remodeling could be considered an integral regulatory process underlying metastasis, further suggesting ESRP1 as an important novel target gene for FGFR2 inhibitors to prolong survival and slow disease progression in PC (Figure 3). This evidence concerns the gene FGFR2 and pachyonychia congenita.